CN116999348A - 一种超分子双a烟酰胺的制备方法与应用 - Google Patents
一种超分子双a烟酰胺的制备方法与应用 Download PDFInfo
- Publication number
- CN116999348A CN116999348A CN202310989569.4A CN202310989569A CN116999348A CN 116999348 A CN116999348 A CN 116999348A CN 202310989569 A CN202310989569 A CN 202310989569A CN 116999348 A CN116999348 A CN 116999348A
- Authority
- CN
- China
- Prior art keywords
- nicotinamide
- supermolecule
- double
- bis
- retinol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title claims abstract description 282
- 235000005152 nicotinamide Nutrition 0.000 title claims abstract description 138
- 239000011570 nicotinamide Substances 0.000 title claims abstract description 138
- 229960003966 nicotinamide Drugs 0.000 title claims abstract description 138
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 98
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 75
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 50
- 229960003471 retinol Drugs 0.000 claims abstract description 49
- 235000020944 retinol Nutrition 0.000 claims abstract description 49
- 239000011607 retinol Substances 0.000 claims abstract description 49
- 239000002608 ionic liquid Substances 0.000 claims abstract description 40
- FFNOWYSCJOKVCL-UHFFFAOYSA-N 1-hydroxy-3,3-dimethylbutan-2-one Chemical compound CC(C)(C)C(=O)CO FFNOWYSCJOKVCL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 13
- -1 nicotinamide, phospholipid Chemical class 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000003921 oil Substances 0.000 claims description 32
- 235000019198 oils Nutrition 0.000 claims description 32
- 239000011261 inert gas Substances 0.000 claims description 28
- 239000003755 preservative agent Substances 0.000 claims description 20
- 230000002335 preservative effect Effects 0.000 claims description 20
- 239000003381 stabilizer Substances 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 210000003022 colostrum Anatomy 0.000 claims description 14
- 235000021277 colostrum Nutrition 0.000 claims description 14
- 238000010008 shearing Methods 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 13
- 150000003904 phospholipids Chemical class 0.000 claims description 13
- 238000000265 homogenisation Methods 0.000 claims description 12
- 229930002330 retinoic acid Natural products 0.000 claims description 12
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 12
- 229960001727 tretinoin Drugs 0.000 claims description 10
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 9
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 9
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 9
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- 230000005496 eutectics Effects 0.000 claims description 8
- 239000004519 grease Substances 0.000 claims description 8
- 238000004090 dissolution Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 229920000570 polyether Polymers 0.000 claims description 7
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 6
- 229940032094 squalane Drugs 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims description 5
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims description 5
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 5
- 229930014456 matrine Natural products 0.000 claims description 5
- NFSPEJVQHPVXEP-UHFFFAOYSA-N nonanedioic acid;pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1.OC(=O)CCCCCCCC(O)=O NFSPEJVQHPVXEP-UHFFFAOYSA-N 0.000 claims description 5
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 5
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 4
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- HXLQIJRKKFMNGU-UHFFFAOYSA-N 2-hydroxybenzoic acid;pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1.OC(=O)C1=CC=CC=C1O HXLQIJRKKFMNGU-UHFFFAOYSA-N 0.000 claims description 3
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 3
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 2
- 229940035437 1,3-propanediol Drugs 0.000 claims description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 2
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 claims description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 claims description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 2
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 claims description 2
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 2
- 229940074928 isopropyl myristate Drugs 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 2
- 229940057910 shea butter Drugs 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 1
- PPVDHXWQWABSBC-UHFFFAOYSA-N 2-(2,6-diethyl-4-hydroxy-3,5-dimethoxyphenyl)-2-hexyl-1,3-dioxane-4,6-dione Chemical compound CCC=1C(OC)=C(O)C(OC)=C(CC)C=1C1(CCCCCC)OC(=O)CC(=O)O1 PPVDHXWQWABSBC-UHFFFAOYSA-N 0.000 claims 1
- 241000208822 Lactuca Species 0.000 claims 1
- 229940116365 diethylhexyl syringylidenemalonate Drugs 0.000 claims 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229940068965 polysorbates Drugs 0.000 claims 1
- 239000008347 soybean phospholipid Substances 0.000 claims 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 16
- 238000005516 engineering process Methods 0.000 abstract description 15
- 229940101578 microlipid Drugs 0.000 abstract description 13
- 239000002775 capsule Substances 0.000 abstract description 10
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract description 9
- 230000007794 irritation Effects 0.000 abstract description 7
- 230000003712 anti-aging effect Effects 0.000 abstract description 6
- 230000002087 whitening effect Effects 0.000 abstract description 6
- 239000011149 active material Substances 0.000 abstract 2
- 239000008406 cosmetic ingredient Substances 0.000 abstract 1
- 239000012466 permeate Substances 0.000 abstract 1
- 229940067631 phospholipid Drugs 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 68
- 210000003491 skin Anatomy 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 17
- 238000001514 detection method Methods 0.000 description 16
- 230000037303 wrinkles Effects 0.000 description 14
- 239000002537 cosmetic Substances 0.000 description 13
- 238000005538 encapsulation Methods 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 230000001153 anti-wrinkle effect Effects 0.000 description 9
- 239000006071 cream Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003094 microcapsule Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000011076 safety test Methods 0.000 description 5
- 239000004721 Polyphenylene oxide Substances 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 4
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 102000004363 Aquaporin 3 Human genes 0.000 description 3
- 108090000991 Aquaporin 3 Proteins 0.000 description 3
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229960000735 docosanol Drugs 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229960002446 octanoic acid Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000010495 camellia oil Substances 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000004609 retinol derivatives Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000727169 Prinsepia utilis Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- HSHMTDVEKPAEGS-UHFFFAOYSA-N diethyl 2-hexylpropanedioate Chemical compound CCCCCCC(C(=O)OCC)C(=O)OCC HSHMTDVEKPAEGS-UHFFFAOYSA-N 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 229950005578 tidiacic Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种超分子双A烟酰胺的制备方法与应用,由离子液体、视黄醇、羟基频哪酮视黄酸酯、烟酰胺、磷脂等原辅料制备而来;利用离子液体微脂囊技术先将离子液体层(含双A)包裹水溶活性物层(含烟酰胺)后,再用水共包裹离子液体层和水溶活性物层,形成独特双层球状结构的超分子双A烟酰胺,可降低离子性,不影响配方体系的粘度;显著提高脂溶性和水溶性成分的包封率,稳定性进一步提高,且进一步促渗活性物;超分子双A烟酰胺到达靶点具备长效缓释作用,避免高浓度接触进而显著降低功效活性物的刺激性,安心护肤养肤,实现精准且全面的速效长效共存的抗衰美白等功效,为类似功效化妆品成分提供了新思路和新方法。
Description
技术领域
本发明涉及化妆品技术领域,特别涉及超分子双A烟酰胺的制备方法与应用。
背景技术
维生素A即视黄醇,是最早被发现的维生素。在化妆品领域,维生素A具有举足轻重的地位,具有抗衰老、祛痘、美白淡斑等皮肤护理功能。在化妆品领域,视黄醇被称为抗衰的“黄金标准”。但视黄醇不稳定,同时刺激性也比较强,使用含视黄醇的化妆品后,皮肤可能会出现泛红、脱皮、刺痛等状况。为降低视黄醇的刺激性,通过侧链修饰,一系列的视黄醇衍生物被应用于化妆品领域抗衰类活性成分。羟基频哪酮视黄酸酯(HPR)则是第三代视黄醇衍生物,与视黄酸的分子结构类似,不需转化为视黄酸能直接发挥作用,是最理想的视黄醇衍生物。具有调节表皮及角质层新陈代谢的功能,可以抗衰老,能减少皮脂溢出,淡化表皮色素,起到预防皮肤衰老、预防痤疮、美白淡斑等作用,在保证视黄醇强大功效的同时又极大地降低了其刺激性。
视黄醇及其衍生物具有促进胶原蛋白合成的能力,从而使皮肤具有韧性和弹性,并且有助于增加皮肤的保水性能,其抗衰关键因素于皮肤内转变为视黄酸。其中,全反式视黄酸为视黄酸常见的活性形式,可增加水通道蛋白3(AQP3)在正常人体皮肤中的表达,增加细胞膜水的通透性,参与水的分泌、吸收及细胞内外平衡的调节。但AQP3的过量表达会增加经皮水分流失,引起皮肤干燥、敏感以及加速衰老。烟酰胺一方面能够抑制全反式视黄酸诱导的AQP3过度表达,降低带来的皮肤敏感性;另一方面能够干扰黑色素的转运,并具有很好的抗糖化作用,有助于皮肤美白,从而提亮肤色;再而烟酰胺能够激活ATP,增加胶原蛋白的合成,并具有很好的协同能力,可与其他的抗皱成分一起使用。
视黄醇及羟基频哪酮视黄酸酯均不溶于水,又因其具有全反式共轭双键,在高温、活性氧存在的条件下易降解、变色;同时视黄醇类活性物少量添加就极易发生局部炎症,又因烟酰胺的酰胺结构易被氧化产生烟酸,对皮肤造成极大刺激。再者,皮肤自有的屏障功能,功效活性物很难透过角质层到达皮肤深层结构发挥作用,生物利用度低,无法充分发挥功能活性物的功效。
发明内容
鉴于以上,本申请的目的在于提供一种超分子双A烟酰胺的制备方法与应用,具有以下创造点:先将离子液体层包裹水溶活性物层后,再用水共包裹离子液体层和水溶活性物层,形成水包离子液体包水溶活性物的独特双层球状结构的超分子双A烟酰胺。
本发明提供了一种超分子双A烟酰胺,包括了离子液体、油脂、活性成分、磷脂、乳化剂、抗氧化剂、稳定剂、防腐剂、pH调节剂、去离子水的原辅料制备而来;所述的活性成分为视黄醇、羟基频哪酮视黄酸酯、烟酰胺;
其中,超分子双A烟酰胺中的视黄醇含量为0.1-20.0%,羟基频哪酮视黄酸酯的含量为0.1-10.0%,烟酰胺含量为0.1-10.0%,其中视黄醇、羟基频哪酮视黄酸酯的质量百分比优选为5:1-1:1。
其中,超分子双A烟酰胺中的超分子溶剂含量为0.1-10.0%,所述超分子双A烟酰胺中的离子液体是烟酰胺壬二酸、烟酰胺水杨酸、椰油苦参碱等任意一种及其组合,其中离子液体中的分子摩尔比范围1:4-4:1。
其中,所述的超分子双A烟酰胺中的油脂含量为1.0-30.0%,所述油脂为角鲨烷、辛酸/癸酸甘油三酯、异十二烷、异十六烷、异壬酸异壬酯、肉豆蔻酸异丙酯、乳木果油、白池花籽油、辛基十二醇等任意一种及其组合。
其中,所述的超分子双A烟酰胺中的磷脂的含量为0.1-5.0%,所述磷脂为卵磷脂、氢化卵磷脂、大豆卵磷脂、蛋黄卵磷脂、合成磷脂、磷脂酰丝氨酸、磷脂酰肌醇、磷脂酰胆碱等任意一种及其组合。
其中,所述的超分子双A烟酰胺中的乳化剂含量为0.1-10.0%,所述的乳化剂为聚山梨醇酯类、PEG-8辛酸/癸酸甘油酯类、PEG-100硬脂酸酯类、鲸蜡硬脂醇聚醚类、月桂醇聚醚类、聚甘油-2单硬脂酸酯、硬脂醇聚醚类、甘油硬脂酸酯类、PEG-40氢化蓖麻油等任意一种及其组合。
其中,所述的超分子双A烟酰胺中的抗氧化剂的含量为0.1-5.0%,所述抗氧化剂为生育酚乙酸酯、生育酚琥珀酸酯、焦亚硫酸钠、抗坏血酸棕榈酸酯、亚丁香基丙二酸二乙基己酯等任意一种及其组合。
其中,所述的超分子双A烟酰胺中的稳定剂的含量为0.1-5.0%,所述稳定剂为EDTA-2Na、油酸钠、甘油、丁二醇、1,3-丙二醇等任意一种及其组合。
其中,所述的超分子双A烟酰胺中防腐剂的含量为0.1-5.0%,所述的超分子双A烟酰胺的防腐剂有戊二醇、辛酰羟肟酸、甘油辛酸酯、乙基己基甘油、三氯叔丁醇、对羟基苯乙酮、己二醇中任意一种及其组合。
本发明提供了一种超分子双A烟酰胺制备方法,请参阅图1,图1为本发明提供一种超分子双A烟酰胺制备方法实施例的流程图,如图所示,其包括如下步骤:
(1)内层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量烟酰胺、烟酰胺类离子盐/共晶加至适量水中,作为内层水相备用;
(2)油相制备:在惰性气体氛围及设定温度条件下,将适宜量的磷脂、抗氧化剂、乳化剂和适量油脂等油相辅料溶解于离子液体中,待溶解完全后,加入最佳量的羟基频哪酮视黄酸酯、视黄醇,配制得油相,备用;
(3)外层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量防腐剂、稳定剂等加至余量水中,作为外层水相备用;
(4)初乳制备:维持惰性气体氛围及温度,在剪切条件下先将外层水相缓慢加入到油相当中,包合完全后,将整体于剪切条件下加至外层水相中,获得初乳;
(5)超分子双A烟酰胺:经高压均质或微射流最佳参数处理后,得到最终产品超分子双A烟酰胺。
其中,作为优选方案,所述步骤(1)中视黄醇、羟基频哪酮视黄酸酯与油脂质量比为1:1-1:3。
其中,油相制备温度条件为:40~80℃,优选为55~65℃。所述搅拌转速为100-1000rpm,优选500-800rpm,所述搅拌的时间为0.5~2h。
其中,高压均质机优选两步高压均质机,均质条件为:一级阀均质压力400-1500bar,优选600-1000bar;二级阀为0-200bar,优选50-150bar;均质次数2-15遍,优选6-10遍;均质温度0-80℃,优选为40-60℃。
其中微射流的均质条件为压力400-1500bar,优选600-1000bar;均质次数2-15遍,优选6-10遍;均质温度0-80℃,优选为40-60℃。
本发明成功制备了一种化妆品用超分子双A烟酰胺,解决了双A和烟酰胺在化妆品等领域中使用的局限性。
为使本发明的目的、技术方案及效果更加清楚、明确,以下对本发明进一步详细说明。应当理解,此处所描述的具体实施例仅用以解释本发明,并不用于限定本发明。
本发明的与现有技术的有益效果:本发明由离子液体、视黄醇、羟基频哪酮视黄酸酯、烟酰胺、磷脂等原辅料制备而来;利用离子液体微脂囊技术先将离子液体层(含双A)包裹水溶活性物层(含烟酰胺)后,再用水共包裹离子液体层和水溶活性物层,形成独特双层球状结构的超分子双A烟酰胺,可降低离子性,不影响配方体系的粘度。具体优点如下:
(1)降低离子性:超分子微脂囊技术可降低离子液体的离子性,直接添加至水乳霜等任意配方中,不影响配方体系的粘度,同时提高配方体系的稳定性;
(2)高包封率:利用双层结构可显著同时提高脂溶性和水溶性成分的包封率,稳定性进一步提高,同时离子液体协同微脂囊进一步增强双A烟酰胺的促渗效果,实现精准且全面的速效长效共存的抗衰美白等功效;
(3)长效且低刺激:所制备的超分子双A烟酰胺进入皮肤到达靶点可进一步缓慢释放,具备长效缓释作用,避免高浓度接触进而显著降低功效活性物的刺激性,安心护肤养肤,可直接应用于化妆品等相关行业,应用更加广泛及便利。
附图说明
图1为本发明一种超分子双A烟酰胺的制备方法较佳实施例的流程图;
图2为一种超分子双A烟酰胺粒径及PDI结果图;
图3为一种超分子双A烟酰胺外观稳定性结果图;
图4为一种超分子双A烟酰胺透射电镜表征图;
图5为一种超分子双A烟酰胺的粒径稳定性图(实施例2);
图6为一种超分子双A烟酰胺中视黄醇的含量稳定性图(以视黄醇定量);
图7为多效低刺激高稳定超分子双A烟酰胺产品包封率;
图8为一种超分子双A烟酰胺与游离活性物的体外皮内滞留对比结果图(实施例2与对比示例2);
图9为一种超分子双A烟酰胺与游离活性物的人真皮成纤维细胞毒性测试对比结果图;
图10为一种超分子双A烟酰胺的鸡胚绒毛尿囊膜刺激性测试对比结果图;
图11为一种超分子双A烟酰胺配方与游离活性物配方的多次皮肤刺激试验结果;
图12为一种超分子双A烟酰胺的人真皮成纤维细胞抗皱和紧致功效(Collagen I和MMP-1)测试结果图;
图13为一种超分子双A烟酰胺使用28天前后人体紧致功效(a.皮肤弹性R2、b.紧致度F4、c.下颌线角度)效果对比图;
图14为一种超分子双A烟酰胺使用28天前后人体抗皱功效PRIMOS检测(a.眼角皱纹面积、b.眼角皱纹长度、c.眼角皱纹数量)结果;
图15为一种超分子双A烟酰胺使用28天前后人体抗皱功效VISIA-CR检测(a.眼角皱纹面积、b.眼下皱纹面积、c.脸颊皱纹面积、d.皮肤平滑度)结果对比图;
图16为一种超分子双A烟酰胺人体功效使用28天前后人体眼角皱纹图;
图17为一种超分子双A烟酰胺人体功效使用28天前后人体下颌线图;
图18为一种超分子双A烟酰胺示意图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。此处所描述的具体实施例和对比例仅仅用以解释本发明,并不用于限定本发明。
应当理解,如图1至图18所示,本发明提供一种超分子双A烟酰胺的制备方法与应用,具体实施例及应用如下:
实施例1
本实施例一种超分子双A烟酰胺的制备方法,包括以下步骤:
(1)内层水相制备:在惰性气体氛围及设定温度条件下,称取5份烟酰胺、1份烟酰胺水杨酸共晶加至适量水中,作为内层水相备用;
(2)油相制备:在惰性气体氛围及设定温度条件下,将5份氢化卵磷脂、1份抗坏血酸棕榈酸酯、5份PEG-100硬脂酸酯、适量角鲨烷等油相辅料溶解于20份椰油苦参碱离子液体,待溶解完全后,加入5份羟基频哪酮视黄酸酯、5份视黄醇,配制得油相,备用;
(3)外层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量防腐剂、稳定剂等加至余量水中,作为外层水相备用;
(4)初乳制备:维持惰性气体氛围及温度,在剪切条件下先将外层水相缓慢加入到油相当中,包合完全后,将整体于剪切条件下加至外层水相中,获得初乳;
(5)超分子双A烟酰胺:经高压均质或微射流最佳参数处理后,得到最终产品超分子双A烟酰胺。
实施例2
本实施例超分子双A烟酰胺的制备方法,包括以下步骤:
(1)内层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量5份烟酰胺、1份烟酰胺壬二酸共晶加至适量水中,作为内层水相备用;
(2)油相制备:在惰性气体氛围及设定温度条件下,将3份氢化卵磷脂、1份生育酚乙酸酯、5份PEG-40氢化蓖麻油和适量辛酸/癸酸甘油三酯等油相辅料溶解于10份椰油苦参碱离子液体中,待溶解完全后,加入3份羟基频哪酮视黄酸酯、5份视黄醇,配制得油相,备用;
(3)外层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量防腐剂、稳定剂等加至余量水中,作为外层水相备用;
(4)初乳制备:维持惰性气体氛围及温度,在剪切条件下先将外层水相缓慢加入到油相当中,包合完全后,将整体于剪切条件下加至外层水相中,获得初乳;
(5)超分子双A烟酰胺:经高压均质或微射流最佳参数处理后,得到最终产品超分子双A烟酰胺。
实施例3
本实施例超分子双A烟酰胺的制备方法,包括以下步骤:
(1)内层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量3份烟酰胺、1份烟酰胺酒石酸离子盐加至适量水中,作为内层水相备用;
(2)油相制备:在惰性气体氛围及设定温度条件下,将2份氢化磷脂、1份生育酚乙酸酯、3份月桂酸聚醚类乳化剂和适量碳酸二辛酯等等油相辅料溶解于5份苦参碱山茶油离子液体中,待溶解完全后,加入2份羟基频哪酮视黄酸酯、4份视黄醇,配制得油相,备用;
(3)外层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量防腐剂、稳定剂等加至余量水中,作为外层水相备用;
(4)初乳制备:维持惰性气体氛围及温度,在剪切条件下先将外层水相缓慢加入到油相当中,包合完全后,将整体于剪切条件下加至外层水相中,获得初乳;
(5)超分子双A烟酰胺:经高压均质或微射流最佳参数处理后,得到最终产品超分子双A烟酰胺。
实施例4
本实施例超分子双A烟酰胺的制备方法,包括以下步骤:
(1)内层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量2份烟酰胺、0.5份烟酰胺壬二酸共晶加至适量水中,作为内层水相备用;
(2)油相制备:在惰性气体氛围及设定温度条件下,将1份氢化磷脂、0.5份生育酚乙酸酯、2份甘油硬脂酸酯类和适量异壬酸异壬酯等油相辅料溶解于5份苦参碱青刺果油离子液体中,待溶解完全后,加入1份羟基频哪酮视黄酸酯、3份视黄醇,配制得油相,备用;
(3)外层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量防腐剂、稳定剂等加至余量水中,作为外层水相备用;
(4)初乳制备:维持惰性气体氛围及温度,在剪切条件下先将外层水相缓慢加入到油相当中,包合完全后,将整体于剪切条件下加至外层水相中,获得初乳;
(5)超分子双A烟酰胺:经高压均质或微射流最佳参数处理后,得到最终产品超分子双A烟酰胺。
实施例5
本实施例超分子双A烟酰胺的制备方法,包括以下步骤:
(1)内层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量1份烟酰胺、0.5份烟酰胺壬二酸共晶加至适量水中,作为内层水相备用;
(2)油相制备:在惰性气体氛围及设定温度条件下,将0.5份氢化磷脂、0.2份生育酚乙酸酯、1份PEG-8辛酸/癸酸甘油酯类和适量辛酸/癸酸甘油三酯等油相辅料溶解于3份苦参碱山茶油离子液体中,待溶解完全后,加入0.5份羟基频哪酮视黄酸酯、1份视黄醇,配制得油相,备用;
(3)外层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量防腐剂、稳定剂等加至余量水中,作为外层水相备用;
(4)初乳制备:维持惰性气体氛围及温度,在剪切条件下先将外层水相缓慢加入到油相当中,包合完全后,将整体于剪切条件下加至外层水相中,获得初乳;
(5)超分子双A烟酰胺:经高压均质或微射流最佳参数处理后,得到最终产品超分子双A烟酰胺。
实施例6
本实施例采用本发明的超分子双A烟酰胺制备超分子双A烟酰胺液体面霜(配方应用),包括以下步骤:
油相制备:以1%角鲨烷、2%辛酸/癸酸甘油三酯、3%聚甘油-2单硬脂酸酯、0.5%十六十八醇、0.5%山嵛醇、0.5%生育酚乙酸酯为油相,于75℃水浴中溶解混合;
水相制备:以3%实施例2中的超分子双A烟酰胺(3%羟基频哪酮视黄酸酯+5%视黄醇+5%烟酰胺)、5%甘油、5.0%丁二醇、3%戊二醇、0.05%EDTA-2Na和余量纯化水作为水相,于室温水浴中溶解;
搅拌混合两相并乳化高速均质,冷却,即得超分子双A烟酰胺液体面霜,作为实施例6。如表1所示,为一种双A烟酰胺超分子双A烟酰胺配方应用(实施示例6)多次皮肤刺激安全性试验结果。
表1为一种双A烟酰胺超分子双A烟酰胺配方应用(实施示例6)多次皮肤刺激安全性试验结果
对比例1游离活性物溶液的制备
称取3%羟基频哪酮视黄酸酯、5%视黄醇、5%烟酰胺搅拌溶解于5%PEG-40氢化蓖麻油溶液中,溶解均匀室温放置不析出,得到游离活性物溶液,作为实施例2的对比示例。
对比例2
本对比示例未作超分子微脂囊技术处理的常规视黄醇衍生物精华乳的制备:
按照常规乳制备方法,以0.09%羟基频哪酮视黄酸酯、0.15%视黄醇、1%角鲨烷、2%辛酸/癸酸甘油三酯、3%聚甘油-2单硬脂酸酯、0.5%十六十八醇、0.5%山嵛醇、0.5%生育酚乙酸酯为油相;以0.15%烟酰胺、5%甘油、5.0%丁二醇、3%戊二醇、0.05%EDTA-2Na和余量纯化水作为水相,于室温水浴中溶解;搅拌混合两相并乳化,冷却,即得未包裹活性物精华乳,作为实施例6的对比示例。
对比示例3
本对比示例未作超分子微脂囊技术包裹处理的游离视黄醇衍生物精华乳的制备:
按照常规乳制备方法,以3%羟基频哪酮视黄酸酯、5%视黄醇、1%角鲨烷、2%辛酸/癸酸甘油三酯、3%聚甘油-2单硬脂酸酯、0.5%十六十八醇、0.5%山嵛醇、0.5%生育酚乙酸酯为油相;以5%烟酰胺、5%甘油、5.0%丁二醇、3%戊二醇、0.05%EDTA-2Na和余量纯化水作为水相,于室温水浴中溶解;搅拌混合两相并乳化,冷却,即得未包裹活性物精华乳,作为实施例2的对比示例。
二、各实施例、对比例的外观、性能测试
1、产品表征
利用动态光散射法分别对实施例2制备得到的超分子双A烟酰胺进行粒径及PDI检测。图2为实施例2的超分子双A烟酰胺的粒径及PDI检测结果图;
利用透射电镜观察实施例2制备得到的超分子双A烟酰胺料体颗粒,图4为实施例2的超分子双A烟酰胺料体的透射电镜表征图;
表明,超分子双A烟酰胺颗粒粒径小(0.1μm左右),且显然地,料体颗粒均一稳定,并对其进行包封率检测,结果见图7,呈现超分子双A烟酰胺技术对功效物的包封率高,均大于90%,显著提升产品促渗效率,并提高产品稳定性。
2、外观及粒径稳定性检测
实施例2制备得到的超分子双A烟酰胺分别于包括室温、-20℃、45℃、光照条件下存放,考察超分子双A烟酰胺的外观稳定性情况,并检测其对应粒径稳定性,图3为实施例2的超分子双A烟酰胺的外观稳定性检测图,从图可知超分子双A烟酰胺在不同温度条件下放置三个月,料体外观稳定无变化;
同时,从图5可见超分子双A烟酰胺于不同储存条件下存放三个月,粒径稳定,说明超分子微脂囊技术可显著提高产品体系的稳定,尤其显著提高了视黄醇类衍生物光热稳定性。
4、活性成份含量稳定性检测
实施例2制备得到的超分子双A烟酰胺分别在室温、-20℃、45℃、光照条件下存放,检测其中视黄醇的含量稳定性,图6为实施例2的超分子双A烟酰胺中视黄醇含量稳定性检测图,从图6可知超分子双A烟酰胺在不同温度条件下放置三个月,对比未进行包裹的游离的视黄醇,超分子双A烟酰胺稳定性样品中视黄醇仅少量降解,而未进行包裹的游离视黄醇,在45℃条件下放置三个月含量降解达50%以上,说明超分子微脂囊技术可显著提高活性物的稳定性,稳定性提高。
体外滞留检测
利用Franz流通池体外透皮模型,检测实施例2制得的超分子双A烟酰胺和对比示例3促渗效果,如图8所示,可见经超分子离子液体微囊技术所得的超分子双A烟酰胺体外皮内滞留量为未作超分子离子液体微脂囊技术处理的游离双A烟酰胺配方的3倍促渗,表明超分子离子液体微脂囊技术显著提高活性物的透皮效率,显著增强功效。
安全性评估测试
检测实施例6应用超分子离子液体微脂囊技术超分子双A烟酰胺制备成的超分子双A烟酰胺液体面霜和对比示例2分别通过细胞毒性检测(见图9)人体斑贴安全测试(见表2)、多次皮肤刺激测试(见图11)以及鸡胚尿囊膜刺激性检测(见图10)进行安全性评估,如表1、图9-11所示,超分子双A烟酰胺的安全性显著优于未作超分子双A烟酰胺技术处理的游离双A烟酰胺配方。如表2所示,为一种超分子双A烟酰胺人体斑贴安全性试验结果;
表2为一种超分子双A烟酰胺人体斑贴安全性试验结果
注:按《化妆品技术规范》(2015年版)7.2中皮肤反应分级标准记录结果。
即:
阴性反应(0)、
可疑反应,仅有微弱红斑(1)、
弱阳性反应(红斑反应);红斑、浸润、水肿、可有丘疹(2)、
强阳性反应(疱疹反应);红斑、浸润、水肿、丘疹、疱疹;反应可超出受试区(3)
极强阳性反应(融合性疱疹反应);明显红斑、严重浸润、水肿、融合性疱疹;反应超出受试区(4)。
细胞抗皱紧致功效检测
依据T/SHRH031-2020《化妆品紧致抗皱功效测试-体外成纤维细胞Ⅰ型胶原蛋白含量测定》对实施例2所得超分子双A烟酰胺对成纤维细胞作用后CollagenⅠ含量及对MMP-1的抑制效果检测,结果见图12显示,通过细胞功效实验,结果呈现超分子双A烟酰胺可提升49.07%的Collagen I含量并抑制38.34%MMP-1(胶原蛋白降解酶)含量,具备显著优异的抗皱、紧致功效。
人体紧致功效检测
以T/TDCA 003-2021化妆品紧致功效检测方法作为检测依据对实施例6制得的超分子离子液体微脂囊技术制备超分子双A烟酰胺液体面霜,按志愿者筛选要求,分别招募30名志愿者,分别使用实施例6以及对比示例2,共使用28天,并于第14、28天检测对应参数。如图13结果呈现见,受试者连续使用28天,实施例6的皮肤弹性R2、皮肤紧致度F4、VISIA-CR下颌线角度均有显著性改善,且均显著优于未作超分子离子液体微脂囊技术处理的游离双A烟酰胺乳即对比示例2,显然地,超分子双A烟酰胺显著增强功效物的紧致功效。
人体抗皱功效检测
以T/CAB 0152-2022化妆品抗皱、紧致、保湿、控油、修护、舒缓七项功效检测方法作为检测依据对实施例6制得的超分子离子液体微脂囊技术制备超分子双A烟酰胺液体面霜,按志愿者筛选要求,分别招募30名志愿者,分别使用实施例6以及对比示例2,共使用28天,并于第14、28天检测对应参数。如图14-15结果呈现见,受试者连续使用28天,实施例6的PRIMOS眼角皱纹面积、PRIMOS眼角皱纹长度、PRIMOS眼角皱纹数量、VISIA-CR眼角皱纹面积、VISIA-CR眼下皱纹面积、VISIA-CR脸颊皱纹面积、VISIA-CR皮肤平滑度均有显著性改善,且均显著优于未作超分子离子液体微脂囊技术处理的游离双A烟酰胺乳即对比示例2,具体见图14-17。显然地,超分子双A烟酰胺显著增强功效物的抗皱功效。
本发明的有益效果是:本发明提供一种超分子双A烟酰胺的制备方法与应用,具有以下创造点:先将离子液体层包裹水溶活性物层后,再用水共包裹离子液体层和水溶活性物层,形成水包离子液体包水溶活性物的独特双层球状结构的超分子双A烟酰胺。具有以下创造性优势,
(1)降低离子性:超分子微脂囊技术可降低离子液体的离子性,直接添加至水乳霜等任意配方中,不影响配方体系的粘度,同时提高配方体系的稳定性;
(2)高包封率:利用双层结构可显著同时提高脂溶性和水溶性成分的包封率,稳定性进一步提高,同时离子液体协同微脂囊进一步增强双A烟酰胺的促渗效果,实现精准且全面的速效长效共存的抗衰美白等功效;
(3)长效且低刺激:所制备的超分子双A烟酰胺进入皮肤到达靶点可进一步缓慢释放,具备长效缓释作用,避免高浓度接触进而显著降低功效活性物的刺激性,安心护肤养肤,可直接应用于化妆品等相关行业,应用更加广泛及便利。
最后应说明的是:以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解;其依然可以对前述实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明实施例技术方案的范围,其均应涵盖在本发明的权利要求和说明书的范围当中。
Claims (10)
1.一种超分子双A烟酰胺,其特征在于,所述超分子双A烟酰胺包括了超分子溶剂离子液体、油脂、活性成分、磷脂、乳化剂、抗氧化剂、稳定剂、防腐剂、pH调节剂、去离子水的原辅料制备而来;所述超分子溶剂含量为0.1-10.0%,所述油脂含量为1.0-30.0%,所述磷脂的含量为0.1-5.0%,所述乳化剂含量为0.1-10.0%,所述抗氧化剂的含量为0.1-5.0%,所述稳定剂的含量为0.1-5.0%,所述防腐剂的含量为0.1-5.0%;
所述活性成分为视黄醇、羟基频哪酮视黄酸酯、烟酰胺;
所述视黄醇含量为0.1-20.0%,所述羟基频哪酮视黄酸酯的含量为0.1-10.0%,所述烟酰胺含量为0.1-10.0%。
2.如权利要求1所述的超分子双A烟酰胺,其特征在于,所述离子液体是烟酰胺壬二酸、烟酰胺水杨酸、椰油苦参碱任意一种及其组合,其中离子液体中的分子摩尔比范围1:4-4:1。
3.根据权利要求1所述的超分子双A烟酰胺,其特征在于,所述油脂为角鲨烷、辛酸/癸酸甘油三酯、异十二烷、异十六烷、异壬酸异壬酯、肉豆蔻酸异丙酯、乳木果油、白池花籽油、辛基十二醇等任意一种及其组合。
4.根据权利要求1所述的超分子双A烟酰胺,其特征在于,所述磷脂为卵磷脂、氢化卵磷脂、大豆卵磷脂、蛋黄卵磷脂、合成磷脂、磷脂酰丝氨酸、磷脂酰肌醇、磷脂酰胆碱任意一种及其组合。
5.根据权利要求1所述的超分子双A烟酰胺,其特征在于,所述乳化剂为聚山梨醇酯类、PEG-8辛酸/癸酸甘油酯类、PEG-100硬脂酸酯类、鲸蜡硬脂醇聚醚类、月桂醇聚醚类、聚甘油-2单硬脂酸酯、硬脂醇聚醚类、甘油硬脂酸酯类、PEG-40氢化蓖麻油任意一种及其组合。
6.根据权利要求1所述的超分子双A烟酰胺,其特征在于,所述抗氧化剂为生育酚乙酸酯、生育酚琥珀酸酯、焦亚硫酸钠、抗坏血酸棕榈酸酯、亚丁香基丙二酸二乙基己酯任意一种及其组合。
7.根据权利要求1所述的超分子双A烟酰胺,其特征在于,所述稳定剂为EDTA-2Na、油酸钠、甘油、丁二醇、1,3-丙二醇任意一种及其组合。
8.根据权利要求1所述的超分子双A烟酰胺,其特征在于,所述防腐剂有戊二醇、辛酰羟肟酸、甘油辛酸酯、乙基己基甘油、三氯叔丁醇、对羟基苯乙酮、己二醇中任意一种及其组合。
9.一种超分子双A烟酰胺的制备方法,其特征在于,包括以下步骤:
(1)内层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量烟酰胺、烟酰胺类离子盐/共晶加至适量水中,作为内层水相备用;
(2)油相制备:在惰性气体氛围及设定温度条件下,将适宜量的磷脂、抗氧化剂、乳化剂和适量油脂等油相辅料溶解于离子液体中,待溶解完全后,加入最佳量的羟基频哪酮视黄酸酯、视黄醇,配制得油相备用;
所述油相制备温度条件为:40~80℃,所述搅拌转速为100-1000rpm,所述搅拌的时间为0.5~2h;
(3)外层水相制备:在惰性气体氛围及设定温度条件下,称取适宜量防腐剂、稳定剂等加至余量水中,作为外层水相备用;
(4)初乳制备:维持惰性气体氛围及温度,在剪切条件下先将外层水相缓慢加入到油相当中,包合完全后,将整体于剪切条件下加至外层水相中,获得初乳;
(5)超分子双A烟酰胺:经高压均质或微射流最佳参数处理后,得到最终产品超分子双A烟酰胺;
所述高压均质机优选两步高压均质机,均质条件为::一级阀均质压力400-1500bar二级阀为0-200bar,均质次数2-15遍,均质温度0-80℃。
10.根据权利要求9所述的双A烟酰胺超分子双A烟酰胺的制备方法,其特征在于,所述微射流的均质条件为压力400-1500bar,优选600-1000bar;均质次数2-15遍,优选6-10遍;均质温度0-80℃,优选为40-60℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310989569.4A CN116999348A (zh) | 2023-08-08 | 2023-08-08 | 一种超分子双a烟酰胺的制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310989569.4A CN116999348A (zh) | 2023-08-08 | 2023-08-08 | 一种超分子双a烟酰胺的制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116999348A true CN116999348A (zh) | 2023-11-07 |
Family
ID=88566929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310989569.4A Pending CN116999348A (zh) | 2023-08-08 | 2023-08-08 | 一种超分子双a烟酰胺的制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116999348A (zh) |
-
2023
- 2023-08-08 CN CN202310989569.4A patent/CN116999348A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3014780B2 (ja) | スキンケア組成物 | |
US20210338634A1 (en) | Putrescine slow-release topical formulations | |
DE10226990A1 (de) | Topisch applizierbare Mikro-Emulsionen mit binärer Phasen- und Wirkstoffdifferenzierbarkeit, deren Herstellung und deren Verwendung, insbesondere zur Versorgung der Haut mit bioverfügbarem Sauerstoff | |
KR20110076068A (ko) | 자기유화형 나노 리포좀/다중층 액정 함유 베지클, 이의 제조방법 및 용도 | |
CN111450003A (zh) | 含黄金香柳提取物的抗初老亮颜营养物及其制备方法和精华液、黄金香柳提取物的提取方法 | |
KR20070081192A (ko) | 오리자놀, 미강유 및 인지질이 내포된 리포좀을유효성분으로 함유하는 화장료 조성물 | |
CN115671018B (zh) | 一种祛痘控油微囊包裹体及其制备方法与应用 | |
WO2017009206A1 (en) | Compositions for topical use | |
JP2010180193A (ja) | 高品質化粧料 | |
CN114796008A (zh) | 一种具有美白保湿功效的超分子组合物的制备方法与应用 | |
EP2818154A1 (en) | Topical skin preparation and healthy skin cell activation agent | |
CN115400046A (zh) | 一种超分子微脂囊霜的制备方法与应用 | |
JP2008074780A (ja) | リポソームの皮膚吸収部位をコントロールする方法及びリポソームの皮膚吸収コントロールリリース剤 | |
CN114588067A (zh) | 羟基频哪酮视黄酸酯高油促渗传递体、制备方法及其应用 | |
CN114931517A (zh) | 一种美白体及其制备方法与应用 | |
Tokton et al. | Development of ellagic acid rich pomegranate peel extract loaded nanostructured lipid carriers (NLCS) | |
US20030017183A1 (en) | Dermatological suspensions(micro-matrix) | |
KR102004147B1 (ko) | 리포좀화된 이데베논을 유효성분으로 포함하는 화장료 조성물 | |
CN108354864B (zh) | 一种具有美白保湿功效的乳液的制备方法 | |
KR101460777B1 (ko) | 여드름 개선용 화장료 조성물 | |
CN117379337A (zh) | 一种视黄醇衍生物超分子微脂囊、其制备方法及应用 | |
CN116999348A (zh) | 一种超分子双a烟酰胺的制备方法与应用 | |
CN115990125A (zh) | 一种长效低刺激多用抗皱超分子组合物的制备方法与应用 | |
CN115778880A (zh) | 一种脂质体及其制备方法与应用 | |
US20050281853A1 (en) | Skin compatible cosmetic compositions and delivery methods therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |